"Lumakras is the first-in-class and best-in-class for patients with KRAS G12C mutated non-small cell lung cancer who failed existing treatment. The reliability of drugs has also increased over the past two years with long-term data, and it is expected that they may be used in combination with other drugs such as immuno-cancer drugs in the future." Kim Hye-ryeon, a professor of oncology at Yonsei Cancer Hospital, expressed the meaning of the launch of the new cancer drug Lumakras.

Lumakras is the first and only KRAS targeted anticancer drug that was approved by the MFDS in February. It targets non-small cell lung cancer KRAS G12C mutations. KRAS gene mutation is common in non-small cell lung cancer. In Asia